Annual Report 2025

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY For the year ended 31 December 2025 51 The United Laboratories International Holdings Limited Annual Report 2025 Attributable to owners of the Company Share capital Share premium Shares held for share award scheme Special reserve Capital reserve Share-based compensation reserve Foreign exchange reserve Retained profits Subtotal Non- controlling interests Total RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 (Note b) (Note a) At 1 January 2024 16,965 3,722,482 – 277,100 1,419,177 6,365 9,534 7,283,155 12,734,778 12,840 12,747,618 Exchange differences arising on translation of foreign operations – – – – – – 549 – 549 – 549 Profit (loss) for the year – – – – – – – 2,659,704 2,659,704 (1,883) 2,657,821 Total comprehensive income (expense) for the year – – – – – – 549 2,659,704 2,660,253 (1,883) 2,658,370 Capital contribution from the non-controlling interest of a subsidiary – – – – – – – – – 36,000 36,000 Dividends recognised as distribution (Note 15) – – – – – – – (1,017,535) (1,017,535) – (1,017,535) Purchase of shares for share award scheme – – (36,465) – – – – – (36,465) – (36,465) Transaction cost attributable to purchase of shares for share award scheme – – (112) – – – – – (112) – (112) Recognition of share-based compensation expense – – – – – 47,364 – – 47,364 – 47,364 Vesting of shares – – 35,539 – – (24,693) – (10,846) – – – Appropriations – – – – 162,188 – – (162,188) – – – At 31 December 2024 16,965 3,722,482 (1,038) 277,100 1,581,365 29,036 10,083 8,752,290 14,388,283 46,957 14,435,240 Exchange differences arising on translation of foreign operations – – – – – – (1,156) – (1,156) – (1,156) Profit (loss) for the year – – – – – – – 2,085,902 2,085,902 (4,820) 2,081,082 Total comprehensive (expense) income for the year – – – – – – (1,156) 2,085,902 2,084,746 (4,820) 2,079,926 Capital contribution from the non-controlling interests of subsidiaries – – – – – – – – – 40,225 40,225 Dividends recognised as distribution (Note 15) – – – – – – – (1,042,496) (1,042,496) – (1,042,496) Issue of new shares 1,431 1,988,450 – – – – – – 1,989,881 – 1,989,881 Purchase of shares for share award scheme – – (41,423) – – – – – (41,423) – (41,423) Transaction cost attributable to purchase of shares for share award scheme – – (130) – – – – – (130) – (130) Recognition of share-based compensation expense – – – – – 14,093 – – 14,093 – 14,093 Vesting of shares – – 40,016 – – (23,074) – (16,942) – – – Appropriations – – – – 102,151 – – (102,151) – – – At 31 December 2025 18,396 5,710,932 (2,575) 277,100 1,683,516 20,055 8,927 9,676,603 17,392,954 82,362 17,475,316 Notes: (a) Capital reserve represents the PRC statutory reserve which must be provided for before declaring dividends to the shareholders as approved by the board of directors in accordance with the PRC regulations applicable to the Company’s PRC subsidiaries until the fund reaches 50% of the registered capital of the respective subsidiaries. (b) Included in special reserve is an amount of RMB203,263,000 which represents the portion of registered capital of the two PRC subsidiaries contributed by certain beneficial owners of the Company. The remaining amount of RMB73,837,000 represents the difference between the carrying amount of the non-controlling interests acquired and the fair value of considerations paid for acquisition of additional interests in subsidiaries in prior years.